somapacitan
Selected indexed studies
- Somapacitan. (, 2012) [PMID:38985924]
- Somapacitan. (, 2006) [PMID:33017113]
- Weekly Somapacitan is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial. (J Clin Endocrinol Metab, 2022) [PMID:36062966]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Efficacy and Safety of Somapacitan Relative to Somatrogon and Lonapegsomatropin in Pediatric Growth Hormone Deficiency: Systematic Literature Review and Network Meta-analysis. (2024) pubmed
- Developments in the Management of Growth Hormone Deficiency: Clinical Utility of Somapacitan. (2024) pubmed
- Somapacitan. (2012) pubmed
- Somapacitan. (2006) pubmed
- Weekly Somapacitan is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial. (2022) pubmed
- Once-weekly Somapacitan is Effective and Well Tolerated in Adults with GH Deficiency: A Randomized Phase 3 Trial. (2020) pubmed
- Utilizing Somapacitan, a Long-acting Growth Hormone Formulation, for the Treatment of Adult Growth Hormone Deficiency: A Guide for Clinicians. (2024) pubmed
- Weekly Somapacitan in GH Deficiency: 4-Year Efficacy, Safety, and Treatment/Disease Burden Results From REAL 3. (2023) pubmed
- Somapacitan in Children Born SGA: 52-Week Efficacy, Safety, and IGF-I Response Results From the Phase 2 REAL5 Study. (2025) pubmed
- Somapacitan: a long-acting growth hormone derivative for treatment of growth hormone deficiency. (2022) pubmed